Astrocytes are the most numerous cells in the central nervous system (CNS). They respond to all forms of major and minor CNS insults through a process known as 'reactive astrocytosis'. Studies using molecular and cellular ablation strategies specific to astrocytes are beginning to highlight the substantial, and little recognized, potential for astrocyte failure to cause pathology and dysfunction in the CNS.
REVIEW ARTICLE

Dysthymia: a review of pharmacological and behavioral factors J Griffiths, AV Ravindran, Z Merali, H Anisman
Dysthymia, a chronic, low-grade form of depression, has a morbidity rate as high as that of major depression, and increases the risk for major depressive disorder. Despite the frequent occurrence of dysthymia, limited information is available concerning the etiology of this illness. The present report provides an overview of the biological and characterological features of dysthymia, comorbid features of the illness, the effectiveness of antidepressant treatments, the influence of stressors in the precipitation and maintenance of the disorder, and both quality of life and psychosocial correlates of the illness. The view is proposed that chronic stressor experiences or stressors encountered early in life lead to persistent alterations of some aspects of neurochemical functioning (eg, sensitization of monoamine processes or coexpression of neuropeptides), culminating in desensitization of other processes. These neurochemical alterations favor the development of the dysthymic state. Moreover, owing to the persistence of neurochemical disturbances, vulnerability to double depression is increased, and in this instance treatment with antidepressants may attenuate the symptoms of major depression, but not those of the basal dysthymic state. Finally, the residual features of depression following treatment may be indicative of underlying neurochemical disturbances, and may also serve to increase the probability of illness recurrence or relapse.
MILLENNIUM ARTICLE
Adult brain neurogenesis and psychiatry: a novel theory of depression BL Jacobs, H van Praag, FH Gage
Based on animal studies, it is proposed that the suppression of the birth of new cells (neurogenesis), in the adult hippocampus, is an important precipitating event in the onset of human clinical depression. This would be produced by stressors and/or endogenous factors, such as genetic predisposition. Moreover, this suppression of neurogenesis in the dentate gyrus of the hippocampus disrupts information processing in brain circuits critical for both memory and cognition and for affect. Reciprocally, it is proposed that the augmentation of neurogenesis, by antidepressant therapies such as SSRIs and ECS, is a critical factor in the recovery from depression. Much of the increase in hippocampal neurogenesis induced by these therapeutic agents may be mediated by increases in serotonergic neurotransmission.
ORIGINAL RESEARCH ARTICLES
Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses A Serretti, E Lattuada, C Lorenzi, R Lilli, E Smeraldi Abnormalities of dopamine transmission are implicated in psychiatric disorders. The dopamine D2 receptor (DRD2) is particularly important within the dopaminergic system because it is a binding site of many psychoactive drugs. It has been extensively studied in all major psychiatric disturbances and, among the many studies so far performed, an association of DRD2 variants with the diagnosis of schizophrenia received considerable interest. Unfortunately this association has been either replicated or not replicated, a frequent event in psychiatric genetics. Therefore this paper aimed to shed light on this debated issue using a large sample of psychotic subjects and analyzing their lifetime symptomatology. More than one thousand inpatients affected by major psychosis and 268 healthy controls were investigated. DRD2 variants were not associated with affected subjects but an association between DRD2 and delusional and disorganized symptomatology independent from diagnoses was observed. Therefore, while coding variants of the DRD2 S311C have not a major role in conferring susceptibility to major psychoses, they could be connected with liability to the symptomatological presentation of major psychoses. The dopamine transporter (DAT) plays a central role in dopaminergic neurotransmission in the human brain. Genetic association studies have used a variable number of tandem repeat (VNTR) polymorphism in the 3Ј-flanking region of the dopamine transporter gene (DAT1) to implicate the DAT in the development of various neuropsychiatric disorders. The authors have examined the possibility that a mutation exists in the coding region of the DAT1 gene which through linkage disequilibrium accounts for the observed associations. The results of the systematic mutation screening approach suggest that the DAT1 gene is highly conserved since only two rare missense substitutions and three silent mutations were detected in the whole coding region. The lack of frequent variants of possible functional relevance indicates that genetic variation in the coding region of the DAT1 gene is not responsible for the previously observed associations with neuropsychiatric disorders. A great degree of scientific interest has been generated concerning the Dopamine Transporter (DAT). Its role in modulating dopamine neuro-transmission suggests that variants of DAT might play a role in several psychiatric disorders, such as Attention Deficit/ Hyperactivity Disorder (ADHD), drug addiction and alcoholism. In order to detect variants in DAT the authors sequenced the human DAT gene. Several polymorphic sites, which are heritable differences in DNA were identified. They subsequently tested for differences at these polymorphic sites between several populations of diseased individuals and individuals without disease. The authors have found that a relationship between variants of DAT and ADHD remains firm, but no relationship of any DAT variant and alcoholism was found.
Human dopamine transporter gene
Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients M Takahashi, O Shirakawa, K Toyooka, N Kitamura, T Hashimoto, K Maeda, S Koizumi, K Wakabayashi, H Takahashi, T Someya, H Nawa Abnormal structural and neurochemical development, which results in abnormal neural circuitry and functions, has been implicated as a cause of schizophrenia. Previous postmortem studies have revealed that the corticolimbic system of schizophrenic patients expresses abnormal levels of synaptic proteins such as AMPA receptors, glutamate decarboxylase, synaptophysin and neuropeptides. Interestingly, diffusible proteins called neurotrophins are known to regulate expression of these synaptic molecules as well as structural brain development, and therefore may be involved in schizophrenic pathology and/or etiology. To test this possibility, levels of neurotrophins and their receptors were determined in postmortem brains of schizophrenic patients and control subjects in the present study. Among the neurotrophins examined, levels of brain-derived neurotrophic factor (BDNF) were specifically elevated in the anterior cingulate cortex and hippocampus. In parallel, the receptor for BDNF (TrkB) was reduced significantly in the corticolimbic structures of patients. However, neither withdrawal of drug treatment in patients nor chronic administration of haloperidol to rats altered the hippocampal level of BDNF. These findings suggest a strong link between impaired neurotrophin signaling and schizophrenia, and support the hypothesis that this disease may involve neurodevelopmental defects in the corticolimbic system.
Association analysis of the GABA A receptor subunit genes cluster on 5q33-34 and alcohol dependence in a Japanese population E-W Loh, S Higuchi, S Matsushita, R Murray, C-K Chen, D Ball
Recent investigations suggest that genetic susceptibility to alcohol dependence may be conferred by GABA A receptor subunit genes. In this study, three genetic variants at the GABA A ␤2, GABA A ␣6, GABA A ␣1 and two at the GABA A ␥2 receptor subunit genes, were examined for association with alcohol dependence in 189 subjects meeting DSM-III-R criteria for this disorder and 152 unrelated controls from a Japanese population. The authors were unable to replicate previous findings demonstrating an association between a variant at the GABA A ␣6 receptor subunit gene and alcohol dependence, although a non-significant trend was observed. However, the NciI RFLP at the GABA A ␥2 receptor subunit gene was associated with alcohol dependence comorbid with antisocial personality disorder. This supports a recent finding reporting an association between the GABA A ␥2 receptor subunit gene and alcohol dependence with criminal record in a Finnish population. Taking into account the effects of multiple comparisons, this result should be interpreted with caution pending replication. ␥-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system. GABA receptors are composed of several different subunits and associated with both a chloride ionophore and specific binding sites for benzodiazepines (BZD). The efficacy of BZD drugs in treating alcohol withdrawal suggests the GABA A /BZD receptor system may have a key role in the mechanism of alcohol's effects. In the rat, variation in alcohol and BZD sensitivity has been correlated with an inherited variant of the GABA A ␣6 receptor. The GABA A ␣6 receptor gene coding region was screened in alcoholism using single strand conformational polymorphism analysis. A relatively abundant amino acid substitution and three synonymous DNA substitutions were detected. The Pro385Ser substitution is located in the second intracellular domain of the receptor adjacent to a putative phosphorylation site. The variant is not associated with alcoholism. chromosomes 1p, 4p, 6q, 7q, 13q, 15q, 16p, 17q, 19q and 22q in Finnish multiplex families A Auranen, T Nieminen, S Majuri, R Vanhala, L Peltonen, I Jä rvelä Family and twin studies have shown that infantile autism has a strong genetic component with the concordance rate for monozygous twins between 69-98% and for dizygous twins ෂ10%. The neurobiological pathway leading to autism is much unknown, and no susceptibility genes have been identified. On the basis of molecular genetic studies performed on autism the authors have analyzed ten previously reported regions on chromosomes 1p, 4p, 6q, 7q, 13q, 15q, 16p, 17q, 19q and 22q. They have studied 17 families with autism spectrum of disorder originating from the isolated Finnish population. None of the previously reported candidate regions showed evidence for genetic linkage Molecular Psychiatry in Finnish families. Consequently, additional loci might be involved in the pathogenesis of autism.
Analysis of autism susceptibility gene loci on
Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia R Joober, C Benkelfat, S Lal, D Bloom, A Labelle, P Lalonde, G Turecki, R Rozen, GA Rouleau Schizophrenia is a highly heritable disease associated with a varied clinical presentation, long-term outcome and response to medication which may reflect differences in the aetiology of the disease. In the present study, two groups of schizophrenic patients were selected on the basis of their long-term response to neuroleptics. Excellent responders and non-responders were both compared to a group of healthy volunteers with regard to a mutation in the methylenetetrahydrofolate reductase (MTHFR) gene. This gene encodes for an enzyme involved in many metabolic pathways and was chosen because it has been found to be associated in some studies with schizophrenia. Treatmentresponders were found to have a significant excess of the allele T form of the MTHFR gene compared to nonresponders and controls. These results suggest that this gene is involved in schizophrenia characterized by a rapid and sustained therapeutic response to typical neuroleptics. Treatment responsiveness may be an important variable when conducting future genetic studies in schizophrenia.
Comparative sequencing and association studies of aromatic L-amino acid decarboxylase in schizophrenia and bipolar disorder G Speight, D Turic, J Austin, B Hoogendoorn, AG Cardno, KC Murphy, R Sanders, G McCarthy, I Jones, F McCandless, N Craddock, MJ Owen, P Buckland, MC O'Donovan The dopamine hypothesis of psychosis underpins most pharmacological treatments for these disorders. Because of this, other genes that interact with the dopamine system in the brain are also considered potential sites at which altered functioning might lead to psychosis. In this study, the authors examined one such modifier of the dopamine system, the gene coding an enzyme called aromatic l-amino acid decarboxylase. They screened this gene for DNA sequence variations that might change the function of the enzyme and looked to see if any such variants are more common in people with either schizophrenia or bipolar disorder (the two most common types of psychosis). However, they conclude that altered function in this gene is very unlikely to contribute to the origins of these disorders.
Glucocorticoid modulation of dopamine-mediated effects on hypothalamic atrial natriuretic factor neurons D Lee, W Huang, D Copolov, AT Lim
Stress is known to precipitate or aggravate the symptoms of schizophrenia. Whereas the neurobiological basis of this effect remains unclear, it may be related to the activation of the hypothalamus-pituitary-adrenal axis, which results in an elevated level of circulating adrenal glucocorticoids. The possibility that the stress hormone, glucocorticoids, may in turn adversely modulate the response of brain cells to dopamine linking to schizophrenic episodes needs to be considered. Employing long-term cultures of important groups of brain cells, we have examined the biochemical effect of this stress hormone. Glucocorticoid treatment was found to induce an aberrant response from a group of brain cells sensitive to dopamine. More interestingly, this effect was due to the suppression of cellular functions mediated through a subtype of dopamine receptors, known as D5 receptors. As D5 receptors play an important role in the negative symptoms of schizophrenia, our findings suggest that stress may adversely affect schizophrenia through a similar mechanism involving the suppression of D5 receptor-mediated effects by the stress hormone, glucocorticoids. J Licinio, MD Editor
